Search for a trial | Research with human participants

1 results

AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135)
MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS
DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS
WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE
RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING
LENALIDOMIDE AND A PROTEASOME INHIBITOR

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-509208-14-00 check the CTIS register for the current data. Primary objective:-To compare the efficacy of elranatamab (Arm A) vs daratumumab + pomalidomide + dexamethasone (Arm C) as measured by…